NeuroSense Therapeutics Statistics
Share Statistics
NeuroSense Therapeutics has 23.99M
shares outstanding. The number of shares has increased by 28.78%
in one year.
Shares Outstanding | 23.99M |
Shares Change (YoY) | 28.78% |
Shares Change (QoQ) | 0.45% |
Owned by Institutions (%) | 3.58% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 5,275 |
FTD / Avg. Volume | 3.52% |
Short Selling Information
The latest short interest is 163.71K, so 0.68% of the outstanding
shares have been sold short.
Short Interest | 163.71K |
Short % of Shares Out | 0.68% |
Short % of Float | 0.83% |
Short Ratio (days to cover) | 1.87 |
Valuation Ratios
The PE ratio is -2.19 and the forward
PE ratio is -2.29.
NeuroSense Therapeutics's PEG ratio is
0.06.
PE Ratio | -2.19 |
Forward PE | -2.29 |
PS Ratio | 0 |
Forward PS | 0.8 |
PB Ratio | 8.64 |
P/FCF Ratio | -2.2 |
PEG Ratio | 0.06 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21,
with a Debt / Equity ratio of 0.03.
Current Ratio | 2.21 |
Quick Ratio | 2.21 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | -31.84 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-600,588.24 |
Employee Count | 17 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.34, so NeuroSense Therapeutics's
price volatility has been higher than the market average.
Beta | 1.34 |
52-Week Price Change | n/a |
50-Day Moving Average | 1.05 |
200-Day Moving Average | 1.07 |
Relative Strength Index (RSI) | 67.29 |
Average Volume (20 Days) | 149,826 |
Income Statement
Revenue | n/a |
Gross Profit | -22K |
Operating Income | -9.9M |
Net Income | -10.21M |
EBITDA | -9.88M |
EBIT | -9.9M |
Earnings Per Share (EPS) | -0.55 |
Full Income Statement Balance Sheet
The company has 3.38M in cash and 73K in
debt, giving a net cash position of 3.31M.
Cash & Cash Equivalents | 3.38M |
Total Debt | 73K |
Net Cash | 3.31M |
Retained Earnings | -36.66M |
Total Assets | 4.58M |
Working Capital | 2.41M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -10.13M
and capital expenditures -3K, giving a free cash flow of -10.14M.
Operating Cash Flow | -10.13M |
Capital Expenditures | -3K |
Free Cash Flow | -10.14M |
FCF Per Share | -0.54 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |